Regeneron and Sanofi’s blockbuster Dupixent has transformed the atopic dermatitis market, with future disruptors in the pipeline.
- Duchenne gene therapy interim trial outcomes “striking” June 6, 2025
- MHRA issues first UK guidance on phage therapies June 5, 2025
- European Council announces progress on pharmaceutical package adoption June 4, 2025
- BioNTech and BMS partner to advance oncology deal worth over $10 billion June 3, 2025
- R&D and tech innovation boosting biopharmaceutical market to 2030 June 2, 2025
- Roche reports long-term capabilities of multiple sclerosis drug May 30, 2025
- Sandoz Launches PYZCHIVA® (Ustekinumab) Autoinjector in Europe June 4, 2025
- Samsung Bioepis Secures Marketing Approval in Korea for its Biosimilar to Amgen’s Bone Cancer Drug Xgeva June 3, 2025
- EMA Issues Positive CHMP Opinions for Fresenius Denosumab Biosimilars June 2, 2025
- Celltrion, Samsung Bioepis, and Organon Receive Interchangeability Designations for Adalimumab Biosimilars June 2, 2025
- FDA Approves Bio-Thera and Hikma’s Ustekinumab Biosimilar May 29, 2025
- Moving Beyond Mitigation: Cracking the Maximizer Code to Protect Patient Affordability June 6, 2025
- Pharmacist Salaries and Employment in 2024: Retail Employment Collapse Offset by Hospital Boom June 3, 2025
- Three Ways GoodRx Is Helping Pharmacies Increase Profitability and Drive Innovation May 30, 2025
- Drug Channels News Roundup, May 2025: MFN Controversy, Plan Sponsors ♥️ Rebates, PBM Profits, and Fun in Congress May 28, 2025
- How the IRA’s Part B Coinsurance Inflation Adjustments Can Raise Seniors’ Drug Costs May 21, 2025
- What’s Next for Retail Pharmacy: Data, Debate, and Disruption (NEW Live Video Webinar) May 20, 2025
- Resetting the Walk-Away Price: How GoodRx Data Reveals New Realities of Prescription Abandonment May 16, 2025